Form 4: Alnylam Director Peter Kellogg Receives Equity Grant

Director Peter N. Kellogg acquired 671 restricted stock units and 1,441 stock options as part of an annual equity incentive grant.

Summary

• Director Peter N. Kellogg was granted 671 restricted stock units (RSUs) on May 20, 2026.
• The director also received a grant of 1,441 stock options with an exercise price of $298.48 per share.
• Both the RSUs and the stock options are scheduled to vest in full on the first anniversary of the grant date, May 20, 2027, or earlier upon specific retirement or resignation conditions.
• Following these transactions, the director holds 1,446 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices with no material impact on company operations.

Positives

• Equity-based compensation aligns the interests of the director with those of long-term shareholders.

Negatives

• The issuance of additional equity awards results in minor dilution to existing shareholders.

Risks

• The value of the granted options is dependent on the future market performance of Alnylam Pharmaceuticals common stock exceeding the $298.48 strike price.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of director compensation.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance practice where board members receive annual equity compensation to ensure long-term alignment with company performance, common among mid-to-large cap biotechnology firms.

Comparison to Industry Standards

• The use of RSUs and stock options with a one-year vesting schedule is consistent with standard director compensation packages in the biopharmaceutical industry.
• The grant size is typical for non-employee directors at companies of similar market capitalization to Alnylam.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity awards.

Next Steps

• Vesting of the granted RSUs and stock options on May 20, 2027.

Key Dates

Keywords

Alnylam Pharmaceuticals, ALNY, Director Compensation, Form 4, Equity Incentive Plan, Insider Transaction